Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

Protea and InSphero collaborate on 3D preclinical imaging

Protea Biosciences based in West Virginia and Swiss biotech firm InSphero announced this week that the companies are combining their 3D technologies into one preclinical imaging platform.

Thumbnail

Vizamyl amyloid PET agent moves one step closer to CE mark

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has given an encouraging nod toward final approval for European marketing of the amyloid-aiming PET agent F-18 flutemetamol (Vizamyl).

Thumbnail

Oligomerix’s anti-tau therapy prospectus to be presented this month

Alzheimer’s therapeutics company Oligomerix announced June 30 that Oligomerix representatives will be presenting the company’s drug development program during poster and scientific sessions at the upcoming Federation of European Neuroscience Societies (FENS) Forum of Neuroscience and the Alzheimer's Association International Conference (AAIC).

Thumbnail

Global companion diagnostics market reached $26B last year and growing

The market for companion diagnostics was valued at $26 billion in 2013 and is projected to grow at an annual growth rate of 22.9 percent during the next decade, according to a new market research report published in June and announced by Research and Markets.

Thumbnail

Angiogenic gene therapy shows promise in phase III SPECT study

Taxus Cardium Pharmaceuticals Group have announced encouraging interim phase III cardiac SPECT imaging results from the international ASPIRE (Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease) trial. Generx Ad5FGF-4 is a potential angiogenic gene therapy for the development of new vascularization. The data was presented June 24 during the 2014 BIO International Convention in the company’s home base of San Diego.

Sofie and PerkinElmer to market preclinical hybrids, biopharmaceuticals

PerkinElmer announced an agreement with Sofie Biosciences this month to commercialize the latter's preclinical PET, 3D CT and X-ray systems.

NCM and ImaginAb to commercialize Zr-89

New York City-based PET radiopharmaceutical development company NCM USA announced this month that ImaginAb will be working on labeling zirconium-89 (Zr-89) and manufacturing practice in a new long-term contract with NCM. 

UT Austin produces alternative means of enriching targets

The University of Texas Austin announced yesterday that a new method for enriching targets for medical isotopes has been developed and patented.